Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials

被引:4
作者
Zhu, Honglin [1 ]
Allwin, Caitlin [1 ]
Bassous, Monica [2 ,3 ]
Pouliopoulos, Antonios [2 ]
机构
[1] Kings Coll London, Fac Life Sci & Med, London, England
[2] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England
[3] Kings Coll London, Sch Canc & Pharmaceut Sci, London, England
关键词
Focused ultrasound; Blood-brain barrier; Microbubbles; Glioblastoma; Brain tumor; PHASE-II; DISRUPTION; GLIOMA; EFFICACY; DELIVERY; SAFETY; GLIOBLASTOMA; PACLITAXEL;
D O I
10.1007/s11060-024-04795-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeBrain tumors, particularly glioblastoma multiforme (GBM), present significant prognostic challenges despite multimodal therapies, including surgical resection, chemotherapy, and radiotherapy. One major obstacle is the limited drug delivery across the blood-brain barrier (BBB). Focused ultrasound (FUS) combined with systemically administered microbubbles has emerged as a non-invasive, targeted, and reversible approach to transiently open the BBB, thus enhancing drug delivery. This review examines clinical trials employing BBB opening techniques to optimise pharmacotherapy for brain tumors, evaluates current challenges, and proposes directions for further research.MethodsA systematic literature search was conducted in PubMed and ClinicalTrials.gov up to November 2023, searching for "ultrasound" AND "brain tumor". The search yielded 1446 results. After screening by title and abstract, followed by full-text screening (n = 48), 35 studies were included in the analysis.ResultsOur analysis includes data from 11 published studies and 24 ongoing trials. The predominant focus of these studies is on glioma, including GMB and astrocytoma. One paper investigated brain metastasis from breast cancer. Evidence indicates that FUS facilitates BBB opening and enhances drug uptake following sonication. Exploration of FUS in the pediatric population is limited, with no published studies and only three ongoing trials dedicated to this demographic.ConclusionFUS is a promising strategy to safely disrupt the BBB, enabling precise and non-invasive lesion targeting, and enhance drug delivery. However, pharmacokinetic studies are required to quantitatively assess improvements in drug uptake. Most studies are phase I clinical trials, and long-term follow-up investigating patient outcomes is essential to evaluate the clinical benefit of this treatment approach. Further studies involving diverse populations and pathologies will be beneficial.
引用
收藏
页码:235 / 252
页数:18
相关论文
共 59 条
  • [1] Dynamics of CNS barriers: Evolution, differentiation, and modulation
    Abbott, NJ
    [J]. CELLULAR AND MOLECULAR NEUROBIOLOGY, 2005, 25 (01) : 5 - 23
  • [2] Focused Ultrasound Treatment, Present and Future
    Abe, Keiichi
    Taira, Takaomi
    [J]. NEUROLOGIA MEDICO-CHIRURGICA, 2017, 57 (08) : 386 - 391
  • [3] First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound
    Abrahao, Agessandro
    Meng, Ying
    Llinas, Maheleth
    Huang, Yuexi
    Hamani, Clement
    Mainprize, Todd
    Aubert, Isabelle
    Heyn, Chinthaka
    Black, Sandra E.
    Hynynen, Kullervo
    Lipsman, Nir
    Zinman, Lorne
    [J]. NATURE COMMUNICATIONS, 2019, 10 (1)
  • [4] P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model
    Adkins, Chris E.
    Mittapalli, Rajendar K.
    Manda, Vamshi K.
    Nounou, Mohamed I.
    Mohammad, Afroz S.
    Terrell, Tori B.
    Bohn, Kaci A.
    Yasemin, Celik
    Grothe, Tiffany R.
    Lockman, Julie A.
    Lockman, Paul R.
    [J]. FRONTIERS IN PHARMACOLOGY, 2013, 4
  • [5] Localized blood-brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions-controlled focused ultrasound
    Anastasiadis, Pavlos
    Gandhi, Dheeraj
    Guo, Yutong
    Ahmed, Abdul-Kareem
    Bentzen, Soren M.
    Arvanitis, Costas
    Woodworth, Graeme F.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (37)
  • [6] Passive Acoustic Mapping with the Angular Spectrum Method
    Arvanitis, Costas D.
    Crake, Calum
    McDannold, Nathan
    Clement, Gregory T.
    [J]. IEEE TRANSACTIONS ON MEDICAL IMAGING, 2017, 36 (04) : 983 - 993
  • [7] Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model
    Aryal, Muna
    Vykhodtseva, Natalia
    Zhang, Yong-Zhi
    Park, Juyoung
    McDannold, Nathan
    [J]. JOURNAL OF CONTROLLED RELEASE, 2013, 169 (1-2) : 103 - 111
  • [8] Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure
    Asquier, Nicolas
    Bouchoux, Guillaume
    Canney, Michael
    Martin, Cyril
    Law-Ye, Bruno
    Leclercq, Delphine
    Chapelon, Jean-Yves
    Lafon, Cyril
    Idbaih, Ahmed
    Carpentier, Alexandre
    [J]. JOURNAL OF NEUROSURGERY, 2020, 132 (03) : 875 - 883
  • [9] Real-Time Passive Acoustic Mapping With Enhanced Spatial Resolution in Neuronavigation-Guided Focused Ultrasound for Blood–Brain Barrier Opening
    Bae, Sua
    Liu, Keyu
    Pouliopoulos, Antonios N.
    Ji, Robin
    Konofagou, Elisa. E.
    [J]. IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 2023, 70 (10) : 2874 - 2885
  • [10] Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
    Batchelor, Tracy T.
    Mulholland, Paul
    Neyns, Bart
    Nabors, L. Burt
    Campone, Mario
    Wick, Antje
    Mason, Warren
    Mikkelsen, Tom
    Phuphanich, Surasak
    Ashby, Lynn S.
    DeGroot, John
    Gattamaneni, Rao
    Cher, Lawrence
    Rosenthal, Mark
    Payer, Franz
    Juergensmeier, Juliane M.
    Jain, Rakesh K.
    Sorensen, A. Gregory
    Xu, John
    Liu, Qi
    van den Bent, Martin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3212 - 3218